Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Cardiotoxicity 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 215Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fluorophotometry × Breast × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡